Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal thiotepa + bevacizumab for leptomeningeal metastases (single-arm phase II)
ChiCTR2500114097Phase 2Not yet recruiting
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thiotepa and bevacizumab in Carcinomatous Meningitis (CM), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Primary endpoint: Intracranial objective response rate (iORR). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
thiotepabevacizumab
03
Conditions
Carcinomatous Meningitis (CM)
Beyond the preview
Go deeper on ChiCTR2500114097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114097.